Hints and tips:
Related Special Reports
...Carolyn Solan, head of external partnerships at consumer drugs group Haleon, which largely produces over-the-counter drugs that can be advertised more easily, said that “while partnering with expert patients...
...He said its products complied with the EU’s “extremely strict” production standards and that its factories were comparable “to the Pfizers of the world”....
...US rival Pfizer in December abandoned plans for a weight-loss pill to be taken twice a day after trials showed significant side effects....
...Andrea Chiarello, Pfizer’s head of EU government affairs, said drugmakers needed more encouragement to discover new antimicrobials and develop drugs....
...Pfizer reported dwindling Covid-19 revenues and weak sales from other products on Tuesday, as it notched a steep drop in sales in 2023....
...But, 10 years this month after Pfizer arrived on the scene, the Frenchman has a fresh challenge: persuading investors that AstraZeneca’s best days are not behind it....
...If Pfizer had followed this route to market for anti-obesity drugs, rather than its own development efforts, its post-Covid plans would be more secure....
...More than a billion dollars worth of Pfizer’s Covid-19 antiviral drugs procured in Europe have been wasted, according to health data, as tight controls over who can receive the medication left millions of...
...Shares of Pfizer fell as much as 7 per cent in after-hours trading on Friday, after the drugmaker cut its sales guidance because of lower demand for its Covid-19 related drugs....
...Shares in Pfizer fell 5 per cent in in New York on Friday after the group said more than half of the participants in its clinical trial for the new drug had dropped out because of side effects....
...He now hopes to bring a case to trial alleging that the product — sold by GSK, Sanofi, Pfizer and Boehringer Ingelheim over many years, caused his disease....
...“It’s unlikely we have high amounts of spare capacity [in the market].”Novo Nordisk, Eli Lilly, and Pfizer all have weight-loss pills under development, which could solve the fill-finish supply issues....
...In December, Pfizer’s shares fell after side-effects forced it to cancel its twice-daily weight loss pill, though it is still pursuing a one-a-day version....
...is by far the world’s largest and most profitable drug market....
...GSK secured approval for Arexvy from the US Food and Drug Administration at the start of May, almost a month before Pfizer’s Abrysvo....
...Other pharmaceutical companies are also racing to develop candidates, such as Pfizer with its late-stage oral GLP-1-RA Danuglipron....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Roche plans to buy immunology company Telavant from Roivant Sciences and Pfizer for more than $7bn, as the drugmaker’s new chief executive seeks to replenish its drug pipeline....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as cases of the disease tick higher....
...Among the notable patent expiries this decade is BMS and Pfizer’s Eliquis blood clot treatment from 2026. BMS will also lose US exclusivity on its lung cancer treatment Opdivo in 2028....
...The US government named 10 drugs made by Eli Lilly, Pfizer and others on Tuesday as the first to face tough new price regulations, in the biggest shake up for the industry in decades....
...Bristol Myers Squibb trades on just seven times earnings while Pfizer is on 20 times. The frenzy for weight loss and diabetes medications is unlikely to fade....
...The results of the study are a promising sign that pain may be treated without opioids, thereby lowering the risk of addiction to a drug that has spurred a health crisis in the US....
...AstraZeneca and Pfizer are both pursuing treatments in pill form although the latter last week abandoned plans for one that would be taken twice a day....
International Edition